Takeda Pharmaceutical Co Ltd
Rusfertide
Polycythemia Vera
Countdown
86days
FDA decision · ~ Sep 30, 2026 estimated
What's at stake
The FDA's approval decision on Rusfertide for Polycythemia Vera is due ~ Sep 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 11h ago
“The Prescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year”